The role and mechanism of IL-21 protein in tumor immunotherapy and its prospects for combination therapy

1. Molecular Characteristics and Receptor Distribution of IL-21 Protein

IL-21 protein belongs to the IL-2 cytokine superfamily and is primarily produced by CD4-positive T cells. Natural killer T cells, follicular helper T cells, and CD8-positive T cells can also partially secrete it, while some hematopoietic cells can produce small amounts. IL-21 receptors are mainly distributed in the spleen, thymus, peripheral blood, and lymph nodes, widely expressed in myeloid and lymphoid cell populations, including B lymphocytes, keratinocytes, dendritic cells, natural killer cells, natural killer T cells, CD4-positive T cells, and CD8-positive T cells. The balance of IL-21 protein in the body is crucial for maintaining normal immune system function.

2. Signal Transduction Pathway of IL-21 Protein

After IL-21 protein binds to the IL-21 receptor α chain and γ chain, it activates JAK1 and JAK3 kinases, which induce the aggregation and phosphorylation of downstream STAT proteins, primarily activating STAT3, partially activating STAT1, and transiently activating STAT5a and STAT5b. The STAT3 dimer enters the nucleus, activating the transcription of target genes, including granzyme A, granzyme B, B-cell lymphoma 6 protein, orphan nuclear receptor gt, tumor suppressor gene Bim, Prdm1, and IL-10, thereby exerting corresponding biological effects. This signaling pathway is the core mechanism by which IL-21 protein performs its immunoregulatory functions.

3. Regulatory Role of IL-21 Protein on CD8-Positive T Cells

IL-21 protein can significantly promote the proliferation of CD8-positive T cells, enhance their secretion of IL-2, interferon-γ, and perforin, and improve their anti-tumor activity. Experimental studies have shown that IL-21 protein can promote the proliferation of both memory and naive CD8-positive T cells in mice, inducing interferon-γ secretion, particularly when combined with IL-15. In contrast, CD8-positive T cells in IL-21 receptor knockout mice exhibit impaired proliferation and cytotoxic functions. In adoptive T cell therapy studies, IL-21-treated T cells show reduced apoptosis rates compared to IL-2-treated counterparts, indicating that IL-21 protein has unique advantages in maintaining T cell survival.

4. Regulatory Role of IL-21 Protein on Natural Killer Cells and Natural Killer T Cells

The anti-tumor effects of natural killer cells have been a research focus, but their low proportion in vivo, difficulty in in vitro expansion, and limited survival time restrict their therapeutic efficacy. Studies have found that membrane-bound IL-21 on antigen-presenting cells can enhance natural killer cell proliferation and cytotoxicity, effectively killing various tumor cells. IL-21 protein can promote interferon-γ secretion in natural killer cells via the IL-21 receptor, enhancing their ability to lyse antibody-coated tumor cells. For natural killer T cells, IL-21 protein synergizes with IL-2 or IL-15 to promote their proliferation and prolong survival, while also increasing granzyme B production. Under CD3/CD8 antibody stimulation, natural killer T cells can further produce IL-21 via autocrine signaling, amplifying their anti-tumor activity.

5. Comparison of Anti-Tumor Effects Between IL-21 Protein and Other Cytokines

In thymoma animal experiments, researchers compared the effects of intraperitoneal injections of IL-2, IL-15, and IL-21 protein on survival rates. All three cytokines improved mouse survival, but IL-21 protein was the most effective, doubling the survival time for half of the mice. When long-term survivors were re-implanted with thymoma, all mice survived beyond 100 days, confirming that survival depends on persistent CD8-positive memory T cells. In melanoma studies, IL-15 or IL-21 protein alone could partially shrink tumors, while their combination led to complete tumor regression and significantly improved long-term survival. These results demonstrate the unique advantages of IL-21 protein in anti-tumor immunity.

6. Application Prospects of IL-21 Protein in CAR-T Combination Therapy

IL-21 protein can regulate the proliferation, differentiation, and activity of T cells, natural killer cells, and natural killer T cells, participating in both innate and adaptive immune responses, making it a promising combination factor in anti-tumor research and CAR-T cell therapy. Compared to other cytokines, IL-21 protein significantly enhances T cell proliferation and anti-tumor effects while improving individual tolerance and reducing side effects. IL-21 protein has entered clinical trials for melanoma, with results consistent with mouse models, showing good tolerability and mild side effects in humans. IL-21 protein offers a promising strategy for balancing efficacy and adverse effects in next-generation CAR-T therapy.

7. Research Outlook

As a key member of the IL-2 cytokine superfamily, IL-21 protein plays a critical role in regulating CD8-positive T cells, natural killer cells, and natural killer T cells. Through mechanisms such as promoting effector cell proliferation, enhancing cytotoxicity, and inhibiting apoptosis, it demonstrates superior anti-tumor effects compared to IL-2 and IL-15. The combination of IL-21 protein with CAR-T cell therapy holds promise for enhancing anti-tumor efficacy while reducing treatment-related toxicity. Future research will further explore the synergistic mechanisms of IL-21 protein with other immunotherapies and its potential in solid tumor treatment, providing new insights and strategies for cancer immunotherapy.

8. Which Manufacturers Provide IL-21 Protein?

Nanjing UA-Bio Technology Co., Ltd. (UA-Bio) has independently developed "IL-21 Protein, Mouse", a high-quality recombinant protein reagent specifically designed for functional regulation of mouse T cells, B cells, and NK cells, as well as preclinical immunotherapy research. This protein is mouse-derived interleukin-21 (IL-21), a key member of the γc family of cytokines, capable of efficiently activating the IL-21 receptor signaling pathway to promote T cell proliferation and differentiation, B cell differentiation into plasma cells, and enhance NK cell cytotoxicity. It provides a stable and reliable standardized tool for mouse tumor immunology models, autoimmune disease mechanism exploration, vaccine development, and related fields.

Nanjing UA-Bio Technology Co., Ltd. is committed to providing cutting-edge, high-quality core reagents and tools for immunology, cell therapy, and innovative drug development. For detailed technical parameters, validation data, or specific application inquiries regarding "IL-21 Protein, Mouse" (Catalog No.: UA040080), please feel free to contact us.